english English    english 中文

Win-Win Fine Chemical Expert Heath Chemicals

E-mail: sales@win-winchemical.com

Whats App: 0086-15325081899

替尔泊肽同款！重磅国产减重药取得顶线结果

2026-05-28
2026年5月5日，科创板上市创新药企业博瑞医药宣布，其自主研发的GLP-1/GIP受体双重激动剂BGM0504注射液，在一项旨在评估其在超重或肥胖受试者中有效性和安全性的III期临床研究（项目编号：BGM0504-III-WL）中取得积极顶线结果。 BGM0504是公司自主研发的GLP-1（胰高血糖素样肽-1）和GIP（葡萄糖依赖性促胰岛素多肽）受体双重激动剂，可激动下游通路，产生控制血糖、减重和治疗代谢相关脂肪性肝炎（MASH）等生物学效应。
Winwin Cheimcal news
Prev: The Domestic GLP-1 Arena: Has a "Trump Card" Just Emerged?
Next: A Tirezepatide Equivalent! Major Domestic Weight-Loss Drug Achieves Topline Results

Win-win chemical wechat

sales@win-winchemical.com Copyright©2007-2024 Win-Win Chemical CO., Limited

Win-Win Chemical,Especialista EM produtos químicos finos EM séries aromáticas: 12289; Série Heterocíclica (Josep 12289; Série Chiral)